Improving AML Classification Using Splicing Signatures
Abstract
Mutations in spliceosomal components are prevalent in myelodysplastic syndromes, but less so in acute myeloid leukemia (AML). However, aberrant splicing is prolific in AML, suggesting deregulated splicing could contribute broadly to tumorigenesis. Elevated stress responses correlate with splicing dysfunction across myeloid malignancies, representing potentially novel therapeutic targets.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 15, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1021
Entities
People
- Teresa V Bowman
Organizations
- Albert Einstein College of Medicine
- American Cancer Society
- National Institutes of Health
- United States Department of Defense